Company Quick10K Filing
Sorrento Therapeutics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 132 $449
10-Q 2019-11-12 Quarter: 2019-09-30
10-Q 2019-08-09 Quarter: 2019-06-30
10-Q 2019-05-15 Quarter: 2019-03-31
10-K 2019-03-15 Annual: 2018-12-31
10-Q 2018-11-09 Quarter: 2018-09-30
10-Q 2018-08-09 Quarter: 2018-06-30
10-Q 2018-05-10 Quarter: 2018-03-31
10-K 2018-03-16 Annual: 2017-12-31
10-Q 2017-11-09 Quarter: 2017-09-30
10-Q 2017-08-09 Quarter: 2017-06-30
10-Q 2017-05-15 Quarter: 2017-03-31
10-K 2017-03-22 Annual: 2016-12-31
10-Q 2016-11-09 Quarter: 2016-09-30
10-Q 2016-08-08 Quarter: 2016-06-30
10-Q 2016-05-10 Quarter: 2016-03-31
10-K 2016-03-15 Annual: 2015-12-31
10-Q 2015-11-16 Quarter: 2015-09-30
10-Q 2015-08-07 Quarter: 2015-06-30
10-Q 2015-05-05 Quarter: 2015-03-31
10-K 2015-03-16 Annual: 2014-12-31
10-Q 2014-11-04 Quarter: 2014-09-30
10-Q 2014-08-06 Quarter: 2014-06-30
10-Q 2014-05-14 Quarter: 2014-03-31
10-K 2014-04-01 Annual: 2013-12-31
10-Q 2013-11-14 Quarter: 2013-09-30
10-Q 2013-08-13 Quarter: 2013-06-30
10-Q 2013-05-15 Quarter: 2013-03-31
10-K 2013-03-25 Annual: 2012-12-31
10-Q 2012-11-08 Quarter: 2012-09-30
10-Q 2012-08-14 Quarter: 2012-06-30
10-Q 2012-05-15 Quarter: 2012-03-31
10-K 2012-03-30 Annual: 2011-12-31
10-Q 2011-11-08 Quarter: 2011-09-30
10-Q 2011-08-12 Quarter: 2011-06-30
10-Q 2011-05-12 Quarter: 2011-03-31
10-K 2011-03-18 Annual: 2010-12-31
10-Q 2010-11-08 Quarter: 2010-09-30
10-Q 2010-08-12 Quarter: 2010-06-30
10-Q 2010-05-14 Quarter: 2010-03-31
10-K 2010-03-25 Annual: 2009-12-31
8-K 2020-01-10 Regulation FD, Exhibits
8-K 2019-12-16 Officers, Exhibits
8-K 2019-12-06 Enter Agreement, Off-BS Arrangement, Sale of Shares, Officers, Exhibits
8-K 2019-11-25 Regulation FD, Exhibits
8-K 2019-10-09 Other Events, Exhibits
8-K 2019-10-07 Enter Agreement, Other Events, Exhibits
8-K 2019-10-01 Enter Agreement, Exhibits
8-K 2019-10-01 Enter Agreement, Exhibits
8-K 2019-09-23 Other Events, Exhibits
8-K 2019-09-20 Officers, Shareholder Vote, Exhibits
8-K 2019-08-12 Other Events
8-K 2019-08-12 Other Events, Exhibits
8-K 2019-07-02 Other Events, Exhibits
8-K 2019-06-28 Enter Agreement, Other Events, Exhibits
8-K 2019-06-20 Other Events, Exhibits
8-K 2019-06-19 Regulation FD, Other Events, Exhibits
8-K 2019-06-17 Leave Agreement
8-K 2019-06-17 Other Events, Exhibits
8-K 2019-06-12 Regulation FD, Exhibits
8-K 2019-06-05 Earnings, Other Events, Exhibits
8-K 2019-06-04 Other Events, Exhibits
8-K 2019-05-21 Regulation FD, Exhibits
8-K 2019-05-13 Earnings, Regulation FD
8-K 2019-05-03 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-04-16 Regulation FD, Exhibits
8-K 2019-04-15 Regulation FD, Exhibits
8-K 2019-04-03 Regulation FD
8-K 2019-03-18 Enter Agreement, M&A, Other Events, Exhibits
8-K 2019-02-14 Earnings, Regulation FD
8-K 2019-01-23 Other Events
8-K 2019-01-22 Regulation FD, Exhibits
8-K 2018-11-13 Enter Agreement, Off-BS Arrangement
8-K 2018-11-08 Other Events, Exhibits
8-K 2018-09-07 Enter Agreement, Off-BS Arrangement, Other Events, Exhibits
8-K 2018-08-24 Officers, Shareholder Vote, Exhibits
8-K 2018-06-13 Enter Agreement, Off-BS Arrangement, Sale of Shares, Regulation FD, Other Events, Exhibits
8-K 2018-04-27 Enter Agreement, Exhibits
8-K 2018-04-16 Amend Bylaw
8-K 2018-04-05 Regulation FD, Exhibits
8-K 2018-03-26 Enter Agreement, Other Events, Exhibits
8-K 2018-03-16 Officers, Exhibits
8-K 2018-02-28 Regulation FD, Exhibits
8-K 2018-02-05 Regulation FD, Exhibits
8-K 2017-09-30

Sorrento Therapeutics Financials

SRNE Metrics, Comps, Filings

Annual | Quarterly

Business

Sorrento Therapeutics, Inc. (Nasdaq: SRNE), together with its subsidiaries (collectively, the "Company", "we", "us" and "our") is a clinical stage and commercial biopharma company focused on delivering innovative and clinically meaningful therapies to patients and their families, globally, to address unmet medical needs. We primarily focus on therapeutics areas in Immune-Oncology and Non-Opioid Pain Management. We also have programs assessing the use of our technologies and products in autoimmune, inflammatory and neurodegenerative diseases.

At our core, we are an antibody-centric company and leverage our proprietary G-MAB™ library and targeted delivery modalities to generate the next generation of cancer therapeutics. Our fully human antibodies include PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2 and CD137 among others.

Our vision is to leverage these antibodies in conjunction with proprietary targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary chimeric antigen receptor T-cell therapy ("CAR-T"), dimeric antigen receptor T-cell therapy ("DAR-T"), antibody drug conjugates ("ADCs") as well as bispecific antibody approaches. Additionally, we acquired Sofusa®, a revolutionary drug delivery system, in July 2018, which delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
IQVIA Holdings (IQV) 31,513,956 35% 21.6 1% 23,068,000 16,287,000 10,706,000 3,739,000 281,000 1,947,000 42,028,956
Incyte (INCY) 18,623,069 95% 46.2 10% 2,947,633 700,442 2,005,891 1,902,736 305,869 372,073 17,205,831
Exact Sciences (EXAS) 14,884,282 74% -79.0 -12% 1,781,943 1,016,411 623,185 460,190 -220,817 -185,830 14,679,224
Charles River (CRL) 6,958,639 9% 17.0 5% 4,625,484 3,146,641 2,448,962 226,417 220,564 517,541 8,796,441
Icon (ICLR) 6,885,543 0% 2,354,255 999,974 0 0 0 0 6,489,692
Exelixis (EXEL) 6,657,219 91% 14.2 39% 1,643,098 154,466 909,761 827,632 641,536 443,501 6,286,330
PRA Health Sciences (PRAH) 6,617,134 0% 21.3 5% 3,442,538 2,278,838 2,932,575 0 158,690 356,273 7,591,452
Syneos Health (SYNH) 5,202,117 11% 16.6 0% 7,396,981 4,573,082 4,546,223 481,502 16,564 470,239 7,829,278
Medpace Holdings (MEDP) 2,312,510 64% 15.7 9% 1,016,861 358,806 786,213 501,312 88,719 146,221 2,292,412
National Research (NRC) 1,399,554 0% 32.5 29% 104,275 78,308 123,546 0 30,382 44,054 1,432,691
Intrexon (XON) 1,235,430 0% -2.9 -76% 655,188 375,965 134,954 0 -497,264 -451,827 1,322,574
Sorrento Therapeutics (SRNE) 449,036 57% -3.1 -45% 587,043 532,427 23,654 13,543 -261,935 -221,277 683,809
Eloxx Pharmaceuticals (ELOX) 360,429 -6.3 -65% 79,039 23,815 0 0 -51,554 -51,432 326,058
Luna Innovations (LUNA) 210,317 47% 12.0 14% 82,189 17,001 56,872 26,780 11,755 15,601 186,780
Anavex Life Sciences (AVXL) 169,983 -5.3 -128% 21,968 4,337 0 0 -28,209 -28,209 148,733
Pieris Pharmaceuticals (PIRS) 118,581 0% -0.5 -31% 130,840 111,355 27,136 0 -39,941 -39,935 18,881
Bioanalytical Systems (BASI) 20,678 30% 16.6 -3% 38,644 28,310 37,816 11,279 -1,280 2,026 33,699
Cleveland Biolabs (CBLI) 18,190 0% -5.1 -99% 3,086 943 277 0 -3,042 -3,030 15,590
Nanoviricides (NNVC) 17,687 -2.0 -63% 13,449 2,848 0 0 -8,424 -7,737 15,131
Tenax Therapeutics (TENX) 3,335 0.4 -143% 9,664 1,044 0 0 -13,816 -13,811 -5,072

Balance Sheet ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash3,4675,09131,66771,90239,03882,39820,42954,592
Accounts Receivable
Inventory
PP&E9881,4813,3722,2777,24612,70719,34524,384
Assets4,5696,78292,582141,541343,519401,586431,613624,087
Accounts Payable2254402,1541,6561,3398,2829,91113,817
Long-Term Debt8764,80512,1469,22947,1075,211361,800
Liabilities35958425,77332,828202,581315,084225,003416,587
Stockholders' Equity4,2096,19766,809108,713145,15280,037199,568209,472
Income Statement ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue52958483,3373,0603,10211,26921,193
Cost of Revenue42,0431,9508113,9457,060
Gross Profit41,2941,1102,2917,32414,133
R&D2,5703,8309,01723,98331,34342,17555,53276,963
SG&A1,2011,6066,3179,98720,13224,21938,33263,638
Tax11163,001234-6,274
Net Income-3,236-4,845-21,911-34,657-50,074-63,93711,109-212,526
Cash Flow ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating-2,743-3,797-16,490-28,764-42,069-70,892-99,180-111,767
Cash Investing-1,052-548-503-10,59112,552-17,452-16,529-21,195
Cash Financing1,9845,97043,56979,590-3,347131,74053,675325,998